[1] De Vincentis A, Vespasiani-Gentilucci U, Costanzo L, et al. The multifaceted spectrum of liver cirrhosis in older hospitalised patients: analysis of the REPOSI registry. Age Ageing, 2021,50(2):498-504.
[2] de Franchis R, Bosch J, Garcia-Tsao G, et al. Baveno Ⅶ- Renewing consensus in portal hypertension. J Hepatol, 2022,76(4):959-974.
[3] Merkel C, Bolognesi M, Bellon S, et al. Prognostic usefulness of hepatic vein catheterization in patients with cirrhosis and esophageal varices. Gastroenterology, 1992,102(3):973-979.
[4] Bernardi M, Servadei D, Trevisani F, et al. Importance of plasma aldosterone concentration on the natriuretic effect of spironolactone in patients with liver cirrhosis and ascites. Digestion, 1985,31(4):189-193.
[5] European Association for the Study of the Liver.EASL clinical practice guidelines on the management of ascites, spontaneous bacterial peritonitis, and hepatorenal syndrome in cirrhosis. J Hepatol, 2010,53(3):397-417.
[6] 中华医学会肝病学分会. 肝硬化腹水及相关并发症的诊疗指南. 传染病信息, 2017,30:前插1-前插17.
[7] Moore KP, Wong F, Gines P, et al. The management of ascites in cirrhosis: report on the consensus conference of the International Ascites Club. Hepatology, 2003,38(1):258-266.
[8] Gerbes AL, Bertheau-Reitha U, Falkner C, et al. Advantages of the new loop diuretic torasemide over furosemide in patients with cirrhosis and ascites. A randomized, double blind cross-over trial. J Hepatol, 1993,17(3):353-358.
[9] Caraceni P, Tufoni M, Zaccherini G, et al. On-treatment serum albumin level can guide long-term treatment in patients with cirrhosis and uncomplicated ascites. J Hepatol, 2021,74(2):340-349.
[10] Krag A, Møller S, Henriksen JH, et al. Terlipressin improves renal function in patients with cirrhosis and ascites without hepatorenal syndrome. Hepatology, 2007,46(6):1863-1871.
[11] Arroyo V, Ginés P, Rimola A, et al. Renal function abnormalities, prostaglandins, and effects of nonsteroidal anti-inflammatory drugs in cirrhosis with ascites. An overview with emphasis on pathogenesis. Am J Med, 1986,81(2B):104-122.
[12] Ge PS, Runyon BA. Treatment of Patients with Cirrhosis. N Engl J Med, 2016,375(8):767-777.
[13] Ginés P, Arroyo V, Quintero E, et al. Comparison of paracentesis and diuretics in the treatment of cirrhotics with tense ascites. Results of a randomized study. Gastroenterology, 1987,93(2):234-241.
[14] Salerno F, Badalamenti S, Incerti P, et al. Repeated paracentesis and i.v. albumin infusion to treat ′tense′ ascites in cirrhotic patients. A safe alternative therapy. J Hepatol, 1987,5(1):102-108.
[15] Fernández-Esparrach G, Guevara M, Sort P, et al. Diuretic requirements after therapeutic paracentesis in non-azotemic patients with cirrhosis. A randomized double-blind trial of spironolactone versus placebo. J Hepatol, 1997,26(3):614-620.
[16] Boyer TD, Haskal ZJ. The role of transjugular intrahepatic portosystemic shunt (TIPS) in the management of portal hypertension: update 2009. Hepatology, 2010,51(1):306.
[17] Yang Z, Han G, Wu Q, et al. Patency and clinical outcomes of transjugular intrahepatic portosystemic shunt with polytetrafluoroethylene-covered stents versus bare stents: a meta-analysis. J Gastroenterol Hepatol, 2010,25(11):1718-1725.
[18] Bureau C, Garcia-Pagan JC, Otal P, et al. Improved clinical outcome using polytetrafluoroethylene-coated stents for TIPS: results of a randomized study. Gastroenterology, 2004,126(2):469-475.
[19] Ochs A, R?ssle M, Haag K, et al. The transjugular intrahepatic portosystemic stent-shunt procedure for refractory ascites. N Engl J Med, 1995,332(18):1192-1197.
[20] Anand BS. Drug treatment of the complications of cirrhosis in the older adult. Drugs Aging, 2001,18(8):575-585.
[21] Salerno F, Borroni G, Moser P, et al. Survival and prognostic factors of cirrhotic patients with ascites: a study of 134 outpatients. Am J Gastroenterol, 1993,88(4):514-519.
[22] Kamimura K, Sakamaki A, Kamimura H, et al. Considerations of elderly factors to manage the complication of liver cirrhosis in elderly patients. World J Gastroenterol, 2019,25(15):1817-1827.
[23] 宁波, 李笑, 柴宁莉, 等. 老年人肝硬化食管胃静脉曲张的临床研究. 中国实验诊断学, 2021,25(11):1625-1627.
[24] Villanueva C, Albillos A, Genescà J, et al. β blockers to prevent decompensation of cirrhosis in patients with clinically significant portal hypertension (PREDESCI): a randomised, double-blind, placebo-controlled, multicentre trial. Lancet, 2019,393(10181):1597-1608.
[25] European Association for the Study of the Liver. EASL Clinical Practice Guidelines for the management of patients with decompensated cirrhosis. J Hepatol, 2018,69(2):406-460.
[26] Simonetto DA, Liu M, Kamath PS. Portal hypertension and related complications: diagnosis and management. Mayo Clin Proc, 2019,94(4):714-726.
[27] Lo GH, Liang HL, Chen WC, et al. A prospective, randomized controlled trial of transjugular intrahepatic portosystemic shunt versus cyanoacrylate injection in the prevention of gastric variceal rebleeding. Endoscopy, 2007,39(8):679-685.
[28] Avgerinos A, Nevens F, Raptis S, et al. Early administration of somatostatin and efficacy of sclerotherapy in acute oesophageal variceal bleeds: the European Acute Bleeding Oesophageal Variceal Episodes (ABOVE) randomised trial. Lancet, 1997,350(9090):1495-1499.
[29] Levacher S, Letoumelin P, Pateron D, et al. Early administration of terlipressin plus glyceryl trinitrate to control active upper gastrointestinal bleeding in cirrhotic patients. Lancet, 1995,346(8979):865-868.
[30] Garcia-Tsao G, Bosch J. Management of varices and variceal hemorrhage in cirrhosis. N Engl J Med, 2010,362(9):823-832.
[31] Villanueva C, Escorsell À. Optimizing general management of acute variceal bleeding in cirrhosis. Current Hepatology Reports, 2014,13(3):198-207.
[32] Tan PC, Hou MC, Lin HC, et al. A randomized trial of endoscopic treatment of acute gastric variceal hemorrhage: N-butyl-2-cyanoacrylate injection versus band ligation. Hepatology, 2006,43(4):690-697.
[33] de Franchis R. Expanding consensus in portal hypertension: report of the baveno Ⅵ consensus workshop: stratifying risk and individualizing care for portal hypertension. J Hepatol, 2015,63(3):743-752.
[34] Garcia-Tsao G, Sanyal AJ, Grace ND, et al. Prevention and management of gastroesophageal varices and variceal hemorrhage in cirrhosis. Hepatology, 2007,46(3):922-938.
[35] Tzeng WS, Wu RH, Lin CY, et al. Prediction of mortality after emergent transjugular intrahepatic portosystemic shunt placement: use of APACHE Ⅱ, Child-Pugh and MELD scores in Asian patients with refractory variceal hemorrhage. Korean J Radiol, 2009,10(5):481-489.
[36] Escorsell À, Pavel O, Cárdenas A, et al. Esophageal balloon tamponade versus esophageal stent in controlling acute refractory variceal bleeding: a multicenter randomized, controlled trial. Hepatology, 2016,63(6):1957-1967.
[37] Cárdenas A, Ginès P, Uriz J, et al. Renal failure after upper gastrointestinal bleeding in cirrhosis: incidence, clinical course, predictive factors, and short-term prognosis. Hepatology, 2001,34(4 Pt 1):671-676.
[38] Shaheen NJ, Stuart E, Schmitz SM, et al. Pantoprazole reduces the size of postbanding ulcers after variceal band ligation: a randomized, controlled trial. Hepatology, 2005,41(3):588-594. |
